ScopusElsevier Scopus
Status
Active
Coverage
2016–2026
Source type
Journal
Open access
Yes
CiteScore
81.6
Best quartile
Q1 · 99th pctile
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Genetics | 1 / 357 | 99th | Q1 |
| Cancer Research | 2 / 233 | 99th | Q1 |
Signal Transduction and Targeted Therapy
ISSN 2059-3635 · 2095-9907
Publisher: Springer Nature
Scopus · Q1WoS · SCIEOpen AccessONOS APC
Is Signal Transduction and Targeted Therapy indexed in Scopus? Yes — actively indexed in Scopus, coverage 2016–2026, best quartile Q1, CiteScore 81.6.
Is Signal Transduction and Targeted Therapy in Web of Science? Yes — indexed in the Science Citation Index Expanded.
Is Signal Transduction and Targeted Therapy open access? Yes — it is an open-access journal, listed in DOAJ.
81.6
CiteScore 2025
Scopus
Q1
Best quartile
99th percentile
3
Indexed in
major indexes
Web of ScienceClarivate (SCIE/SSCI/AHCI/ESCI)
ABDCAustralian Business Deans Council 2025
Not listed in ABDC.
DOAJDirectory of Open Access Journals (live)
Checking DOAJ…
FT50Financial Times research list
Not listed in FT50.
UT DallasUTD top-100 business research
Not listed in UT Dallas.
ONOS · APC coveredOne Nation One Subscription (Govt of India)
Authors affiliated with an ONOS-subscribed Indian institution can publish in this journal with the Article Processing Charge (APC) covered centrally under One Nation One Subscription — no personal APC payment.
Eligibility depends on your institution and the current ONOS list, which is subject to revision — verify before submitting.
Check the ONOS APC portal Official sources & links
Related journals
Explore this journal in the interactive dashboard →
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.